ICU - LMF Acquisition Opportunities Inc

Momentum: Bearish

Recent News

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference - SeaStar Medical Holding ( NASDAQ:ICU )

Benzinga • 1 week, 3 days ago • score: -0.02

DENVER, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- SeaStar Medical Holding Corporation ICU, a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its participation in the upcoming HC ...

Neutral

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 1 week, 3 days ago • score: -0.03

DENVER, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- SeaStar Medical Holding Corporation ( Nasdaq: ICU ) , a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its participation in the ...

Neutral

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

GlobeNewswire • 1 week, 6 days ago • score: 0.07

IJME publication of QUELIMMUNE therapy for pediatric AKI shows a potential for hospitals to incur no out-of-pocket costs for 6 days of treatment.

Neutral

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

GlobeNewswire • 1 month, 1 week ago • score: -0.04

DENVER, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- SeaStar Medical Holding Corporation ( Nasdaq: ICU ) , a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first ...

Neutral

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury ( AKI )

GlobeNewswire • 1 month, 1 week ago • score: 0.00

Trial now over 60% enrolled with 125 of 200 anticipated patients ...

Neutral

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire • 1 month, 2 weeks ago • score: 0.09

DENVER, July 31, 2025 ( GLOBE NEWSWIRE ) -- SeaStar Medical Holding Corporation ( Nasdaq: ICU ) , a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced it has entered into a definitive ...

Neutral

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury ( AKI ) from the First 20 SAVE Surveillance Registry Patients

GlobeNewswire • 1 month, 3 weeks ago • score: 0.09

DENVER, July 22, 2025 ( GLOBE NEWSWIRE ) -- SeaStar Medical Holding Corporation ( Nasdaq: ICU ) , a commercial-stage healthcare company, announced today positive preliminary results from the SAVE Surveillance Registry which is assessing the use of the QUELIMMUNE therapy in the treatment of ...

Neutral

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

GlobeNewswire • 1 month, 4 weeks ago • score: 0.12

Highest Rated Children's Medical Centers Now Employ QUELIMMUNE for Ultra-Rare Cases of Pediatric AKI ...

Neutral

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - SeaStar Medical Holding ( NASDAQ:ICU )

Benzinga • 2 months ago • score: 0.08

DENVER, July 10, 2025 ( GLOBE NEWSWIRE ) -- SeaStar Medical Holding Corporation ICU, a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced it has entered into a definitive agreement ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$5.79

52W Low

$0.31

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.97

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-8.13

EV/Revenue (<3 favorable)

22.52

P/S (TTM) (<3 favorable)

28.96

P/B (<3 favorable)

6.64

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.95%

Institutions (25–75% balanced)

6.98%

Shares Outstanding

27,914,600

Float

27,648,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

As of 2025-06-30 (Overview)

Revenue (TTM)

766,000

Gross Profit (TTM)

739,000

EPS (TTM)

-1.85

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-5.20%

ROE (TTM) (>15% strong)

N/A

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0286

0.0295

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025